Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Introduces Nyloxin for Pets - a Treatment for Moderate to Severe Chronic Pain in Companion Animals
September 27, 2010

Nyloxin for Pets is the newest treatment for moderate to severe chronic pain in companion animals. It will be available for sale in an everyday strength through retailers and in a professional strength through veterinarian offices.

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, introduced today Nyloxin for Pets, a new pain reliever aimed at treating moderate to severe chronic pain in companion animals.

“Companion animals play an important role in our homes and communities and are, oftentimes, considered extended members of the family,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As pet owners, many of us will seek out new, innovative and safe treatments for our pets as they become older and less agile. I believe that both pet owners and veterinarians will prefer the safety and efficacy profile offered by Nyloxin for Pets over alternative pain relievers that contain opiates, acetaminophen and other potentially harmful pharmaceutical ingredients,” he added.

According to a 2009 survey conducted by the American Pet Products Association, 93.6 million cats and 77.5 million dogs were owned as pets in the United States. Additionally, the same report published sales for pet supplies, including over-the-counter medicines, totaling $10.48 billion for the same period.

“Nyloxin for Pets offers the opportunity to expand our Nyloxin brand into the large and growing animal health and wellness industry,” explained David Isserman, Chief Marketing Officer of Nutra Pharma Corporation. “As we move forward with this launch, we plan to align ourselves with qualified pet care distributors that can provide the necessary support for national market penetration,” he concluded.

Nyloxin for Pets will be available in an everyday strength sold through retailers and in an extra strength sold only through veterinarian offices. Additionally, Nyloxin for Pets will be specifically formulated to treat moderate to severe chronic pain from hip dysplasia, arthritis, and joint inflammation.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Introducing Nyloxin for Pets should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics